CD8A and gastric cancer: Many studies have shown that TMB, CD8+ TILs, and PD-L1 expression correlate with the efficacy of immunotherapy [42–44]; however, the association between these markers and the clinical benefit of gastric cancer immunotherapy is uncertain [45].